# A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

> **NCT01712061** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 226 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** PF-04634817
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01712061
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2015-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712061, "A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01712061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*